Objective Little is known about the information providers share with patients when ordering a
co-test, or combined human papillomavirus (HPV) and Papanicolaou (Pap) test, for cervical …

Background The human papillomavirus (HPV) test, administered alone without the
Papanicolaou (Pap) test, was recently recognized as a cervical cancer screening option in …

Background: Cervical cancer screening has shifted toward human papillomavirus (HPV)-
based testing, but uptake of primary HPV screening in the United States is unknown and …

Objective Cervical cancer screening using the human papillomavirus (HPV) test and Pap
test together (co-testing) is an option for average-risk women≥ 30 years of age. With normal …

Objective To determine patient knowledge and preferences about primary human
papillomavirus (HPV) testing. Design Cross-sectional survey. Setting Two family practice …

Background: Updated risk-based guidelines for cervical cancer screening (CCS) allow for
individualized screening that minimizes unnecessary testing. However, these guidelines are …

Background: Current cervical cancer screening guidelines include the option of lengthening
the screening interval to 5 years for average-risk women aged 30–65 years when screened …

Cervical cancer screening guidelines in the United States were revised in 2018 to include
the option of primary human papillomavirus (HPV) testing. The transition to this screening …

Background: Guidelines for cervical cancer screening have been updated to include human
papillomavirus (HPV) testing, which is more sensitive compared to cytology in detecting …

Background: Adjunct human papillomavirus (HPV) testing with cervical cytology (Pap test) is
one option that can increase screening intervals for women aged≥ 30 years who have …